Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04677413 · ClinicalTrials.gov registry record · Phase 1

Ultra-fractionated Radiotherapy for Rectal Cancer

A Phase 1 study of Rectal Cancer, sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
Phase 1
Development phase
27
Enrollment target
1
Study location

NCT04677413 is a Phase 1 study of Rectal Cancer that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 27 participants, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04677413, a Phase 1 study of Rectal Cancer, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
Phase 1
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

The rationale of this clinical trial is to assess the feasibility of selective non-operative management for locally advanced rectal cancer using dose-escalated ultra-fractionated short course radiation therapy interdigitated with chemotherapy. We believe delivering short course radiotherapy over a prolonged interval, at escalated doses and with concurrent chemotherapy may be feasible and allow for improved clinical response.

Conditions Studied

Interventions

  • RADIATION Ultrafractionated radiotherapy for rectal cancer

Study Locations (1)

Texas

  • UT Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2021-06-03
Est. Completion 2026-06
Phase Phase 1

What the Registry Record Tells You About NCT04677413

The ClinicalTrials.gov registry entry for NCT04677413 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ultrafractionated radiotherapy for rectal cancer is the first listed.

NCT04677413 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04677413 about?

NCT04677413 is a clinical study titled "Ultra-fractionated Radiotherapy for Rectal Cancer". The rationale of this clinical trial is to assess the feasibility of selective non-operative management for locally advanced rectal cancer using dose-escalated ultra-fractionated short course radiation therapy interdigitated with chemotherapy. We believe delivering short course radiotherapy over a p...

What is the current status of trial NCT04677413?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2021-06-03. Estimated completion is 2026-06.

What conditions does trial NCT04677413 study?

This clinical trial studies the following conditions: Rectal Cancer.

What interventions are being tested in trial NCT04677413?

The interventions under investigation include: Ultrafractionated radiotherapy for rectal cancer (RADIATION).

Who is sponsoring clinical trial NCT04677413?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04677413 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.